V. Haurigot

发表

IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice

J. Agudo, E. Ayuso, V. Jiménez, 2008, Diabetologia.

Increased Intraocular Insulin-like Growth Factor-I Triggers Blood-Retinal Barrier Breakdown*

E. Ayuso, V. Haurigot, J. Ruberte, 2009, The Journal of Biological Chemistry.

Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

E. Ayuso, V. Haurigot, J. Ruberte, 2013, The Journal of clinical investigation.

Robust ZFN-mediated genome editing in adult hemophilic mice.

Y. Doyon, Jeffrey C. Miller, P. Gregory, 2013, Blood.

AAV-mediated pancreatic overexpression of Igf1 counteracts progression to autoimmune diabetes in mice

J. Agudo, V. Jiménez, A. Casellas, 2017, Molecular metabolism.

Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice.

J. Agudo, E. Ayuso, V. Haurigot, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

V. Haurigot, H. Stedman, J. F. Wright, 2010, Blood.

Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs

V. Haurigot, H. Stedman, J. F. Wright, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

In vivo gene therapy for Mucopolysaccharidosis type III (Sanfilippo syndrome): A new treatment horizon.

V. Haurigot, F. Bosch, Sara Marcó, 2019, Human gene therapy.

Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID

V. Haurigot, J. Ruberte, F. Bosch, 2017, Human molecular genetics.

In vivo gene transfer to pancreatic beta cells by systemic delivery of adenoviral vectors.

J. Agudo, E. Ayuso, V. Haurigot, 2004, Human gene therapy.

Toward a gene therapy for neurological and somatic MPSIIIA

V. Haurigot, F. Bosch, 2013, Rare diseases.

Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes

D. Scott, A. D. De Groot, V. Haurigot, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer.

E. Ayuso, V. Haurigot, F. Bosch, 2012, Human gene therapy.

In vivo genome editing restores hemostasis in a mouse model of hemophilia

Hojun Li, Frederic D. Bushman, Katherine A. High, 2011, Nature.

High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency

J Montane, E. Ayuso, V. Haurigot, 2010, Gene Therapy.

Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal

V. Haurigot, F. Bosch, A. Andaluz, 2021, Molecular therapy. Methods & clinical development.

Inhibition of hepatitis C virus replication using adeno‐associated virus vector delivery of an exogenous anti–hepatitis C virus microrna cluster

V. Haurigot, L. Couto, Shangzhen Zhou, 2010, Hepatology.

Long-Term Retinal PEDF Overexpression Prevents Neovascularization in a Murine Adult Model of Retinopathy

V. Haurigot, J. Ruberte, F. Bosch, 2012, PloS one.

FGF21 gene therapy as treatment for obesity and insulin resistance

F. Mulero, V. Jiménez, A. Casellas, 2018, EMBO molecular medicine.

Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease.

E. Ayuso, A. Casellas, V. Haurigot, 2004, The Journal of clinical investigation.

Treatment of Diabetes and Long-Term Survival After Insulin and Glucokinase Gene Therapy

C. Mann, E. Ayuso, V. Haurigot, 2013, Diabetes.

Gene Therapy for Diabetes

V. Jiménez, V. Haurigot, F. Bosch, 2016 .

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

V. Haurigot, J. Ruberte, F. Bosch, 2016, JCI insight.

Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.

V. Haurigot, J. Ruberte, F. Bosch, 2015, Human molecular genetics.

Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC

V. Haurigot, J. Ruberte, F. Bosch, 2016, Disease Models & Mechanisms.

Insulin-like Growth Factor 2 Overexpression Induces β-Cell Dysfunction and Increases Beta-cell Susceptibility to Damage*

J. Agudo, V. Jiménez, A. Salavert, 2015, The Journal of Biological Chemistry.

Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs

E. Ayuso, V. Jiménez, V. Haurigot, 2017, Molecular therapy. Methods & clinical development.

Insulin-like Growth Factor I (IGF-I)-induced Chronic Gliosis and Retinal Stress Lead to Neurodegeneration in a Mouse Model of Retinopathy*

V. Haurigot, F. Bosch, P. de la Villa, 2013, The Journal of Biological Chemistry.

Proliferative retinopathies: animal models and therapeutic opportunities.

V. Haurigot, F. Bosch, Pilar Villacampa, 2015, Current neurovascular research.

In vivo genome editing restores hemostasis in a mouse model of hemophilia

F. Bushman, Y. Doyon, David E. Paschon, 2011, Nature.

Robust ZFN-mediated genome editing in adult hemophilic mice.

Y. Doyon, Jeffrey C. Miller, P. Gregory, 2013, Blood.

Modulation of CD8 Modulation of CD8 ++ T cell responses to AAV vectors with IgG- T cell responses to AAV vectors with IgG-derived MHC class II epitopes derived MHC class II epitopes

V. Haurigot, Shangzhen Zhou, F. Mingozzi, 2022 .

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

V. Haurigot, J. Ruberte, F. Bosch, 2016, JCI insight.

In vivo genome editing restores hemostasis in a mouse model of hemophilia

Y. Doyon, David E. Paschon, E. Rebar, 2016 .